Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer.

Our findings establish the clinical significance of TTK as a new biomarker for EC and an as-yet-unknown carcinogenic function. This present study proposes that the therapeutic targeting of TTK might provide a viable approach for the treatment of EC.